{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:23:44Z","timestamp":1791995024545,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.resinv.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T23:48:30Z","timestamp":1708991310000},"page":"339-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9085","authenticated-orcid":false,"given":"Kohei","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Elkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.resinv.2024.02.002_bib2","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 Years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"10.1016\/j.resinv.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.resinv.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2024.02.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","article-title":"Infectious complications in patients treated with immune checkpoint inhibitors","volume":"141","author":"Karam","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1002\/cam4.3532","article-title":"Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy","volume":"9","author":"Kanjanapan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13303","article-title":"Incidence and predictors of infections in patients with advanced non\u2010small cell lung cancer treated with checkpoint inhibitor immunotherapies: a monocentric retrospective cohort study","volume":"98","author":"Bavaro","year":"2023","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.resinv.2024.02.002_bib13","doi-asserted-by":"crossref","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib15","article-title":"Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"ofaa067","DOI":"10.1093\/ofid\/ofaa067","article-title":"Development of Mycobacterium avium complex lung disease in patients with lung cancer on immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00364-2022","article-title":"Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Lombardi","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2024.02.002_bib19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib20","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.resinv.2024.02.002_bib21","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2018.12.006","article-title":"Immunosuppression for immune checkpoint-related toxicity can cause pneumocystis jirovecii pneumonia (pjp) in non\u2013small-cell lung cancer (NSCLC): a report of 2 cases","volume":"20","author":"Schwarz","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jinf.2019.10.022","article-title":"Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis","volume":"80","author":"Malek","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.resinv.2024.02.002_bib23","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/1759-7714.13422","article-title":"Opportunistic infections complicating immunotherapy for non-small cell lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000577","article-title":"Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.lungcan.2014.07.001","article-title":"Latent TB infection in newly diagnosed lung cancer patients \u2013 a multicenter prospective observational study","volume":"85","author":"Fan","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48395-8","article-title":"The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse","volume":"9","author":"Shu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2024.02.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2024.02.002_bib29","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti\u2013PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.resinv.2024.02.002_bib31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","article-title":"Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer","volume":"57","author":"Jensen","year":"2018","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.resinv.2024.02.002_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/qjmed\/hcy243","article-title":"Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment","volume":"112","author":"Tsai","year":"2019","journal-title":"QJM: Int J Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2169\/internalmedicine.6002-20","article-title":"Readministration of pembrolizumab after treatment of tuberculosis activated by initial pembrolizumab therapy","volume":"60","author":"Murakami","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2020-0061","article-title":"Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report","volume":"12","author":"Kato","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.resinv.2024.02.002_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.resinv.2024.02.002_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/1759-7714.13821","article-title":"Long\u2010term remission of small cell lung cancer after reactivation of tuberculosis following immune\u2010checkpoint blockade: a case report","volume":"12","author":"Sirgiovanni","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.05.020","article-title":"Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: experience from a single Asian centre","volume":"146","author":"Chan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2024.02.002_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/thoraxjnl-2021-217575","article-title":"Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"77","author":"Zhu","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2024.02.002_bib43","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Japanese Adverse Drug Event Report database n.d. https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0006.html (accessed December 15, 2023).."},{"key":"10.1016\/j.resinv.2024.02.002_bib44","article-title":"Complete remission after immunotherapy-induced abdominal tuberculosis in a patient with advanced nsclc treated with pembrolizumab: a case report","volume":"3","author":"Riudavets","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.resinv.2024.02.002_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1164\/rccm.201706-1248LE","article-title":"Gene expression signatures in tuberculosis have greater overlap with autoimmune diseases than with infectious diseases","volume":"196","author":"Clayton","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lungcan.2021.01.021","article-title":"Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient","volume":"153","author":"Baba","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.02.002_bib47","article-title":"Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy","volume":"34","author":"Okamoto","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.resinv.2024.02.002_bib48","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.6550-20","article-title":"Device-related Mycobacterium mageritense infection in a patient treated with nivolumab for metastatic breast cancer","volume":"60","author":"Koyama","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.arbres.2021.04.014","article-title":"Cavitary Mycobacterium avium complex lung disease developed after immunotherapy","volume":"58","author":"Chi","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.resinv.2024.02.002_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jiac.2021.09.013","article-title":"Vertebral osteomyelitis caused by Mycobacteroides abscessus subsp. abscessus resulting in spinal cord injury due to vertebral body fractures","volume":"28","author":"Omori","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2024.02.002_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3892\/mco.2021.2470","article-title":"Mycobacterium avium complex lung disease in a patient treated with an immune checkpoint inhibitor: a case report","volume":"16","author":"Yamaba","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-023-08537-w","article-title":"Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?","volume":"23","author":"Azzar\u00e0","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib54","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201303-067OC","article-title":"A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan","volume":"11","author":"Morimoto","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2024.02.002_bib56","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease","volume":"22","author":"Namkoong","year":"2016","journal-title":"Japan. Emerg Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib57","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.201806-366OC","article-title":"Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan","author":"Izumi","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2024.02.002_bib58","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jfma.2020.05.019","article-title":"Nontuberculous mycobacterial lung disease epidemiology in Taiwan: a systematic review","volume":"119","author":"Lee","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.resinv.2024.02.002_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.02.002_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.resinv.2024.02.002_bib61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/1061186X.2023.2235098","article-title":"Research advances in immune checkpoint drugs for non-small cell lung cancer","volume":"31","author":"Shen","year":"2023","journal-title":"J Drug Target"},{"key":"10.1016\/j.resinv.2024.02.002_bib62","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.resinv.2024.02.002_bib64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1473-3099(15)00135-8","article-title":"Permutations of time and place in tuberculosis","volume":"15","author":"Elkington","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib65","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"Lazar-Molnar","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2024.02.002_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T cell-derived IFN-\u03b3 plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must Be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.resinv.2024.02.002_bib67","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1\u2013mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.02.002_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf3861","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.resinv.2024.02.002_bib69","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1086\/654932","article-title":"Role played by the programmed death\u20101\u2013programmed death ligand pathway during innate immunity against","volume":"202","author":"Alvarez","year":"2010","journal-title":"Mycobacterium tuberculosis. J Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib70","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52668","article-title":"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1","volume":"9","author":"Tezera","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.resinv.2024.02.002_bib71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1164\/rccm.201908-1506PP","article-title":"Reconsidering the optimal immune response to Mycobacterium tuberculosis","volume":"201","author":"Tezera","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib72","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib73","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1164\/rccm.201206-1035OC","article-title":"Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes","volume":"187","author":"Kartalija","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/318087","article-title":"Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex","volume":"183","author":"Vankayalapati","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2024.02.002_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/srep42004","article-title":"Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2024.02.002_bib76","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/jcm9051331","article-title":"Characteristics of circulating CD4+ T cell subsets in patients with Mycobacterium avium complex pulmonary disease","volume":"9","author":"Han","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2024.02.002_bib77","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/microorganisms9122460","article-title":"T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria infection: pathophysiology and therapeutic perspectives","volume":"9","author":"Lombardi","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.resinv.2024.02.002_bib78","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1469-0691.2011.03555.x","article-title":"Guidelines on interferon-\u03b3 release assays for tuberculosis infection: concordance, discordance or confusion?","volume":"17","author":"Denkinger","year":"2011","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.resinv.2024.02.002_bib79","series-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.resinv.2024.02.002_bib80","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s00262-022-03198-1","article-title":"Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study","volume":"71","author":"Fujita","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.resinv.2024.02.002_bib81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:40Z","timestamp":1761950020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2212534524000273"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.02.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}